The tyrosine phosphatase SHP2, encoded by PTPN11, is required for the survival, proliferation and differentiation of various cell types 1, 2 . Germline activating mutations in PTPN11 cause Noonan syndrome, whereas somatic PTPN11 mutations cause childhood myeloproliferative disease and contribute to some solid tumours. Recently, heterozygous inactivating mutations in PTPN11 were found in metachondromatosis, a rare inherited disorder featuring multiple exostoses, enchondromas, joint destruction and bony deformities 3, 4 . The detailed pathogenesis of this disorder has remained unclear. Here we use a conditional knockout (floxed) Ptpn11 allele (Ptpn11 fl ) and Cre recombinase transgenic mice to delete Ptpn11 specifically in monocytes, macrophages and osteoclasts (lysozyme M-Cre; LysMCre) or in cathepsin K (Ctsk)-expressing cells, previously thought to be osteoclasts. LysMCre;Ptpn11 fl/fl mice had mild osteopetrosis. Notably, however, CtskCre;Ptpn11 fl/fl mice developed features very similar to metachondromatosis. Lineage tracing revealed a novel population of CtskCre-expressing cells in the perichondrial groove of Ranvier that display markers and functional properties consistent with mesenchymal progenitors. Chondroid neoplasms arise from these cells and show decreased extracellular signal-regulated kinase (ERK) pathway activation, increased Indian hedgehog (Ihh) and parathyroid hormone-related protein (Pthrp, also known as Pthlh) expression and excessive proliferation. Shp2-deficient chondroprogenitors had decreased fibroblast growth factor-evoked ERK activation and enhanced Ihh and Pthrp expression, whereas fibroblast growth factor receptor (FGFR) or mitogen-activated protein kinase kinase (MEK) inhibitor treatment of chondroid cells increased Ihh and Pthrp expression. Importantly, smoothened inhibitor treatment ameliorated metachondromatosis features in CtskCre;Ptpn11 fl/fl mice. Thus, in contrast to its pro-oncogenic role in haematopoietic and epithelial cells, Ptpn11 is a tumour suppressor in cartilage, acting through a FGFR/MEK/ERK-dependent pathway in a novel progenitor cell population to prevent excessive Ihh production.
Cartilage tumours, including exostoses, enchondromas and chondrosarcomas, comprise ,20% of skeletal neoplasms 5 . Benign and malignant cartilaginous tumours can arise sporadically, but cartilage tumour syndromes, including hereditary multiple exostoses, the multiple enchondromatosis disorders (Ollier disease and Maffucci syndrome) and metachondromatosis, also exist 6, 7 . The cellular and molecular pathogenesis of most cartilage tumours is incompletely understood.
Metachondromatosis is an autosomal dominant tumour syndrome featuring multiple exostoses and enchondromas 6, 7 . Recently, heterozygous early frameshift or nonsense mutations in PTPN11 were identified in .50% of metachondromatosis cases 3, 4 . PTPN11 encodes the non-receptor protein tyrosine phosphatase SHP2, which is required for RAS/ERK pathway activation in most receptor tyrosine kinase, cytokine receptor, and integrin signalling pathways 1,2 . Germline activating c ii, black arrow), increased bone mineral density (c ii, iv; arrows) and multiple exostoses of knees, ankles and metatarsals (b iv and c ii, iv, vi, viii; arrows) with joint destruction. d, Sagittal sections of metatarsal joints stained with haematoxylin and eosin (H&E; i-iii), Safranin O (iv-vi) and Alcian Blue (vii-ix) showing cartilaginous exostoses and enchondromas (arrows) in Ctsk-KO mice. Images in i, iv, vii are magnified 32, in ii, v, viii 310 and in ii, vi, ix 320. Images in ii, v, viii and iii, vi, ix are magnified (310) views of boxed areas in i, iv, vii and ii, v, viii, respectively. Data shown are representative images; each analysis was performed on at least five mice per genotype. mutations in PTPN11 cause Noonan syndrome, whereas mutations that impair SHP2 catalytic activity cause LEOPARD syndrome (an acronym for multiple lentigines, ECG conduction abnormalities, occular hypertelorism, pulmonic stenosis, abnormal genitalia, retardation of growth and sensorineural deafness), both of which can feature skeletal abnormalities 8 . Somatic activating mutations in PTPN11 are the most common cause of juvenile myelomonocytic leukaemia and contribute to other leukaemias and some solid tumours 1, 2 . Although PTPN11 is a well-established human oncogene, it is unclear how heterozygous loss-of-function PTPN11 alleles cause cartilage neoplasms.
Global Ptpn11 deletion results in early embryonic lethality 9,10 , whereas postnatal deletion has context-dependent effects 1,2 . To assess the role of Shp2 in osteoclasts, we crossed Ptpn11 fl mice 10 to mice expressing Cre under the control of the endogenous LysM 11 or Ctsk 12 promoter. The LysM promoter is active in monocytes, macrophages and osteoclast precursors 11 , whereas the Ctsk promoter reportedly is active only in mature osteoclasts 12, 13 . These crosses generated Ptpn11 fl/1 ;LysMCre and Ptpn11 fl/fl ;LysMCre (hereafter, LysM-control and LysM-knockout (KO)) and Ptpn11 fl/1 ;CtskCre and Ptpn11 fl/fl ;CtskCre (hereafter, Ctskcontrol and Ctsk-KO) mice, respectively ( Fig. 1a ).
Neither LysM-control nor Ctsk-control mice had a discernible phenotype, so we focused all subsequent analyses on LysM-KO and Ctsk-KO mice. Shp2 levels were reduced by .80% in bone-marrow-derived macrophages and osteoclasts in LysM-KO and Ctsk-KO mice (Supplementary Fig. 1a and data not shown). LysM-KO and Ctsk-KO mice were born at the expected Mendelian ratios and appeared to be normal for the first 3 weeks after birth. Subsequently, LysM-KO mice developed mild, age-related osteopetrosis ( Supplementary Fig. 1b and data not shown). By contrast, within 8 weeks after birth, Ctsk-KO mice exhibited a dramatic skeletal phenotype, comprising decreased body length, increased bone mineral density, scoliosis, metaphyseal exostoses and markedly decreased mobility ( Fig. 1b-d and Supplementary Video 1).
Sections of hindlimb paw and knee joints from 12-week-old Ctsk-KO mice revealed multiple exostoses and enchondromas at the metaphyses of their metatarsals and phalanges ( Fig. 1d ), tibiae and femurs ( Supplementary Fig. 1c, d ), and other bones (data not shown), features reminiscent of metachondromatosis. As heterozygous PTPN11 frameshift mutations cause metachondromatosis 3, 4 , these findings indicate that PTPN11 is a cartilage tumour-suppressor gene, and suggest that loss (or silencing) of the remaining PTPN11 allele is required for tumour formation.
To identify the cells responsible for metachondromatosis-like disease in Ctsk-KO mice, we first injected bone marrow from 6-week-old Ctsk-KO and Ctsk-control mice (C57/BL6; CD45.2) into lethally irradiated 3-week-old recipients (B6.SJL; CD45.1). Recipient mice exhibited high chimaerism ( Supplementary Fig. 2a, b ), but did not develop cartilage tumours in over 12 months of observation. Consistent with the osteopetrosis seen in LysM-KO mice, recipients had increased bone mineral density ( Supplementary Fig. 2c ). Clearly, however, cartilage tumours in Ctsk-KO mice are not due to altered osteoclast development or function.
Next, we performed lineage-tracing studies using Rosa26-lox-stoplox-lacZ (R26-LSL-lacZ) or Rosa26-LSL-YFP (R26-LSL-YFP) Cre reporter mice. Notably, CtskCre, but not LysMCre, was expressed in a subset of perichondrial cells within the so-called groove of Ranvier ( Fig. 2a ). Sections from knee joints collected at postnatal day (P)10 revealed expansion of a cluster of Alcian Blue/Safranin O-positive cells in this region in Ctsk-KO, mice, but not in controls ( Fig. 2b , boxed region and Supplementary Fig. 1c ). By postnatal week 2, the yellow fluorescent protein (YFP) 1 cell population had increased and differentiated into ectopic cartilaginous tissue in compound Ctsk-KO;YFP reporter mice ( Fig. 2c , boxed region). Exostoses were palpable at 6 weeks and visible by 8-12 weeks. In compound Ctsk-KO;YFP reporter mice, these lesions consisted of YFP 1 chondroid cells at various stages of development, including proliferating, pre-hypertrophic and hypertrophic b a c 
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chondrocytes, as revealed by cell morphology and Col2a1 and Col10a1 immunostaining (Fig. 2c, d and data not shown). Notably, nearly all chondroid tumour cells were YFP 1 (Fig. 2c and Supplementary Fig. 2d ). Hence, cartilaginous tumours in Ctsk-KO mice (and, by analogy, most likely in metachondromatosis) result from cellautonomous lack of Shp2 in Ctsk 1 cells from the perichondrial groove of Ranvier.
The perichondrial groove of Ranvier is believed to contain chondroprogenitors responsible for circumferential cartilage growth, but these cells are not well-characterized 14, 15 . We used flow cytometry to analyse epiphyseal cartilage cells collected from the distal femurs and proximal tibiae of Ctsk-control;YFP and Ctsk-KO;YFP mice at P10-12. Compared with controls, the frequency of YFP 1 cartilage cells in Ctsk-KO;YFP mice was increased by ,fivefold (Fig. 3a) . Within the YFP 1 cell population, the percentage of cells expressing CD44, CD90 and CD166 (mesenchymal progenitor markers), but not CD31 (endothelial cell marker), also was increased (Fig. 3b) . Staining for the stromal cell antigen Stro-1 in addition to jagged 1, markers associated with presumptive chondroprogenitors in the groove on the basis of BrdU label retention studies 16 , was more intense in Ctsk-KO mice (Fig. 3c ). Moreover, YFP 1 cells were capable of multi-lineage differentiation in vitro, as assessed by Alcian Blue, Oil Red O and Alizarin Red staining, respectively (Fig. 3d ). These data indicate that Shp2 regulates the proliferation of a novel cartilage cell population characterized by Ctsk expression, which we hereafter term Ctsk 1 chondroid progenitors (CCPs).
Multiple pathways control cartilage development and homeostasis 17 . IHH and PTHRP signalling are particularly important, and aberrant regulation of these pathways causes developmental defects and skeletal tumours 18, 19 . We examined chondrogenic gene expression in cartilage tumours from Ctsk-KO mice by quantitative reverse-transcription PCR (qRT-PCR). Consistent with our immunostaining data (Fig. 2d ), Col2a1 and Col10a1 transcripts were increased. Furthermore, Ihh and Pthrp levels were increased substantially ( Fig. 4a and Supplementary Fig. 3a ).
These findings prompted us to ask whether Shp2 regulates Ihh and Pthrp production, and if so, how. During development, cells within the perichondrium make Fgf18, which can signal to adjacent cells via Fgfr3 to suppress Ihh expression 20, 21 . As Shp2 is required for Fgfr signalling in other cell types 1,2 , we suspected that Shp2 might be required for Fgfr3-induced suppression of Ihh expression. We therefore examined the status of Fgfr3 signalling components and Ihh expression in CCPs. Erk activation, as assayed by Tyr 204 Thr 202 phosphorylation, was compromised in the absence of Shp2, whereas Akt (phospo (p)-Ser 473) and Stat1/3 (p-Tyr 807) activation were unaffected (Fig. 4a , Supplementary Fig. 3b and data not shown). Furthermore, consistent with our qRT-PCR data, Ihh messenger RNA and protein were increased in Shp2-deficient CCPs (Fig. 4a ). Ihh antibody specificity was confirmed by immunostaining of growth plate cartilage ( Supplementary Fig. 3c ).
CCPs are rare, rendering their detailed biochemical analysis unfeasible. We therefore tested the effects of Shp2 depletion in ATDC5 chondroid cells by stably expressing either of two short hairpin RNAs (shRNAs) targeting mouse Ptpn11. As in Ctsk-KO mice (Fig. 4a ), Fgf18evoked Erk activation was decreased, whereas Ihh and Pthrp levels were increased in Shp2-deficient cells (Fig. 4b ). Conversely, FGFR (PD173074) or MEK (UO126) inhibition led to enhanced Ihh and Pthrp expression in parental ATDC5 cells (Fig. 4c ).
Ihh signalling evokes Pthrp production 22 . Our data, in addition to previous studies 23 , suggested that increased Ihh levels might be pathogenic in metachondromatosis. If so, then blocking or attenuating Ihh signalling might slow and/or prevent the disease. To test this hypothesis, control (wild-type) and Ctsk-KO mice (9 per group) were gavaged daily with the smoothened inhibitor PF-04449913 (SMOi, 100 mg g 21 body weight) or vehicle control (0.5% methylcellulose), beginning at 5 weeks of age (when early lesions were present) and continuing for the succeeding 4 weeks. Skeletal phenotype was assessed by X-ray, micro-computed tomography (m-CT) and histology. Notably, SMOi treatment significantly reduced the number of exostoses in Ctsk-KO 100  101  102  103  104  100  101  102  103  104  100  101  102  103  104  100  101  102  103  104  100  101  102  103  104   100  101  102  103  104  100  101  102  103  104  100  101  102  103  104  100  101  102  103 LETTER RESEARCH mice ( Fig. 4d and Supplementary Figs 4-7) and markedly improved their mobility ( Supplementary Video 1) , without apparent effects on overall growth rate ( Supplementary Fig. 8 ). Importantly, SMOi levels in treated mice were adequate to suppress Ihh target gene expression in exostoses ( Supplementary Fig. 7b ).
Our findings strongly suggest that metachondromatosis results from loss of SHP2, specifically in CCPs, a heretofore poorly characterized population within the perichondrial groove of Ranvier, which is believed to function as a stem-cell niche for joints 16 and a reservoir for the germinal layer cells of the growth plate 24 . Cells within the groove of Ranvier express high levels of FGFR3 (ref. 25) , and their removal prevents longitudinal bone growth 26 . Emerging evidence shows that groove of Ranvier cells can migrate into articular cartilage 16 , implicating them in maintaining cartilage homeostasis and possibly in degenerative joint diseases, such as osteoarthritis. Indeed, in lineagetracing studies of normal mice, we noticed YFP 1 cells migrating towards articular cartilage ( Supplementary Fig. 9 , arrows, and data not shown). On the basis of our mouse metachondromatosis model, we propose that SHP2, acting downstream of FGFR3 and upstream of the RAS/ERK pathway, regulates CCP proliferation and chondrogenic differentiation. Consequently, PTPN11 deficiency in these cells promotes excessive proliferation, chondrogenic differentiation and cartilage tumours.
Metachondromatosis is associated with heterozygous inactivating mutations in PTPN11, yet Ctsk-control mice are normal, whereas Ctsk-KO mice exhibit metachondromatosis-like features. Although PTPN11 gene dosage effects could differ in mouse and man (and thus 50% reduction in SHP2 level might cause metachondromatosis in humans but not in mice), we think it is more likely that loss of the remaining PTPN11 allele (for example, by loss of heterozygosity or silencing) is required to cause cartilage tumours in metachondromatosis. If so, then unlike its oncogenic role in juvenile myelomonocytic leukaemia, other hematologic malignancies and solid tumours 1,2 , PTPN11 is a tumour suppressor in cartilage. Liver-specific Ptpn11 deletion reportedly results in hepatocellular carcinoma 27 . However, we have not seen liver tumours in our Ptpn11 conditional knockout mice crossed to the same Cre line (F.H. & B.G.N., manuscript in preparation), nor is PTPN11 mutated in human hepatocellular carcinoma. Moreover, our biochemical and pharmacological analysis, together with previous studies, provide a parsimonious and attractive explanation for the 
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Ptpn11 floxed (Ptpn11 fl ) 10 , cathepsin K-Cre (Ctsk-Cre) 12 , Rosa26-LSL-lacZ (R26-LSL-lacZ) 29 , and Rosa26-LSL-YFP (R26-LSL-YFP) 30 Cre reporter mice were on C57BL/6 background. PCR genotyping was performed as described 10, 12, 29, 30 ; conditions are available from W.Y. Animal studies were approved by the Institutional Animal Care and Use Committee at Rhode Island Hospital. Mice of both genders were used for this study. Antibodies and reagents are detailed in Methods. CCPs isolated from epiphyseal cartilage of 2-week-old Ctsk-control;YFP and Ctsk-KO;YFP mice (detailed in Methods) were analysed by flow cytometry or subjected to multi-lineage differentiation assays. For flow cytometry, cells were stained with fluorescence-labelled antibodies, and analysed on a BD LSR II flow cytometer using FlowJo software (TreeStar). YFP 1 cells were purified by using a BD Influx cell sorter (BD Bioscience). ATDC5 cells stably expressing mouse Ptpn11 shRNAs or a scrambled control were generated in pSuper(retro)/puro (Oligoengine). RNA was extracted from cells or laser-dissected lesions using RNeasy (Qiagen), complementary DNA was synthesized using iScript (Bio-Rad), and qRT-PCR was performed with the iQ SYBR Green kit. Values were normalized to Gapdh levels, and are expressed as fold-change over control. Primer sequences are available from W.Y.. Femurs, tibiae and paws were fixed in 4% paraformaldehyde, decalcified in 0.5 M EDTA, and sections (5 mm) were stained with haematoxylin and eosin, Alcian Blue or Safranin O. Immunohistochemistry was performed using peroxidasecoupled secondary antibodies, with diaminobenzidine as the substrate. X-gal staining was performed as described 12 . Digital imaging was performed using Faxitron (plain films) and desktop microcomputed tomographic (m-CT40, Scanco Medical) systems. The number of exostoses was quantified from these images. Immunoblotting and detection by enhanced chemiluminescence (Amersham) were performed as described 10 . Differences between groups were evaluated by Student's t test, with P , 0.05 considered significant.
Full Methods and any associated references are available in the online version of the paper.
